Shopping Cart
- Remove All
- Your shopping cart is currently empty
ARV-393 is a PROTAC degrader targeting BCL6 with the advantage of being highly potent and orally available.ARV-393 recruits BCL6 and E3 ligase cerebellum to rapidly degrade BCL6 through the cell's natural ubiquitin proteasome system for the treatment of diffuse large b-cell lymphoma (DLBCL) and non-Hodgkin's lymphoma (NHL).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $223 | In Stock | |
5 mg | $562 | In Stock | |
10 mg | $892 | In Stock | |
25 mg | $1,820 | In Stock | |
50 mg | $2,830 | In Stock |
Description | ARV-393 is a PROTAC degrader targeting BCL6 with the advantage of being highly potent and orally available.ARV-393 recruits BCL6 and E3 ligase cerebellum to rapidly degrade BCL6 through the cell's natural ubiquitin proteasome system for the treatment of diffuse large b-cell lymphoma (DLBCL) and non-Hodgkin's lymphoma (NHL). |
In vitro | ARV-393 demonstrated potent activity in multiple diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) cell lines, with both DC₅₀ and GI₅₀ values < 1 nM [1]. |
In vivo | In xenograft models, mice were orally administered ARV-393 (3, 10, 30 mg/kg; once daily; for 23 days) to evaluate its in vivo antitumor activity in lymphoma. ARV-393 significantly inhibited tumor growth. [2] |
Alias | ARV393 |
Molecular Weight | 898.42 |
Formula | C46H53ClFN9O7 |
Cas No. | 2851885-95-3 |
Smiles | FC1=C2C(C(=O)N(C2)C3C(=O)NC(=O)CC3)=CC=C1C4CCN(CC4)[C@@H]5C[C@@H](OC6CCN(CC6)C=7N=C(NC=8C=C9C(=CC8)N(C(C)C)C(=O)C(OCC(NC)=O)=C9)C(Cl)=CN7)C5 |
Relative Density. | 1.45 g/cm3 at 20℃ (Predicted) |
Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||
Solubility Information | DMSO: 8.00 mg/mL (8.90 mM), Sonication is recommended. | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.